Loading... (0%)

News + Events


3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

30 April 2019

San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) in patients with…

Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

13 February 2019

Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for 3-V Biosciences’ FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40), a first-in-class,…

3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®

16 October 2017

Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class fatty acid synthase (FASN) inhibitors at the upcoming AASLD meeting. Poster #1972 “Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in…